
Greener way of SDA

BE FINANCIALLY INDEPENDENT

Disclaimer – Below Analysis is NOT a BUY/SELL/HOLD Recommendation. It is for educational purpose and it can be used for educational purposes further. There could be lot of things which might have been missed in my analysis either due to lack of information or oversight etc.. Do your own diligence & contact your expert financial adviser before making any investment decision.
Incorporated in 1996, Tatva Chintan Pharma Chem Limited is a specialty chemicals manufacturing company. It is engaged in the manufacture of structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for super capacitor batteries and pharmaceutical & agrochemical intermediates & other specialty chemicals (PASC).
Business —
One of the leading producers with entire range of PTCs in India and one of the key producers across the globe
2nd largest manufacturer of SDAs for Zeolites globally and the largest commercial supplier in India
TCPCL is the largest producer of Glymes in India and third largest in the world.
Largest producer of electrolyte salts for super capacitor batteries in India






END USER INDUSTRIES — Growing industries in coming decade
Moats —
TCPCL is one of the few companies globally that uses Electrolysis process in organic synthesis. Advanced chemistries in process and for commercial development, manufacture and approvals, it takes 1-6 years for new players to enter this field.
In many of the segments, it is amongst top five players
Strengths
Considering the wide range of applications of our products, TCPCL can cater to customers across wide spectrum of Chemical Industries
which ensures a sustainable business model.
Diversified product portfolio has helped accelerate growth and in innovating and thus retain both new and existing customers
Diversified esteemed clientele
Necessary certifications in place : ISO 9001:2015 ISO 14001:2015 BS OHSAS 18001:2007
Advantages of Electrolyses
Region of operation
The company exports most of its products to over 25 countries, including the US, China, Germany, Japan, South Africa and the UK.
It reduced % revenue dependency on top 10 customers from 60% to 47%

Shareholding
Promoter has sufficient skin in game with holding ~79% and other prominent players holding 10% more


Some triggers and updates from recent Q3Fy22 Concall
Getting approvals from two large customers

Getting into EV domain with supercapacitor batteries and new horizon opening up faster than anticipated

New versatile product development in Continuous flow chemistry us also capable in other applications including EV

Comfortable Leading market share in almost all operating domains

Mindset of accepting which projects

Delayed expansion –currently scheduled for Nov 22
Delay in semiconductors supplies impacting SDA in FY23 as well (current anticipation is till FY22)
Slow ramp up of electrolyte salts than projected
Approvals for new PASC delayed
Increase in raw material and frieght costs is already impacting margins, further increase will hurt next two quarters badly in terms of margins if it happens ( Q4FY22, Q1FY23)
They have to be seen in terms of huge growth runway available but current valuations don’t give that comfort to take large positions with risks on execution and inflation
Looks better to give time to company and see how it performs and keep accumulating in background in small tranches. That may work.
Your strategy can be different than mine. Your selection of company might be different than mine. So lets not be a BLIND FOLLOWER
Disclaimer – Analysis is NOT a BUY/SELL/HOLD Recommendation. It is for educational purpose and it can be used for educational purposes further. There could be lot of things which might have been missed in my analysis either due to lack of information or oversight etc.. Do your own diligence & contact your expert financial adviser before making any investment decision.
In case you have any questions/ queries, please feel free to reach me through Contact Form
Do spread the word among your peers, family members or anyone who can benefit from this blog and asked them to subscribe. But be selfish and take care of yourself first by subscribing before they do.
Enjoy the day and your life. Don’t forget, we are alone in this grand universe and may not get a chance to live again.


The data has been compiled from various sources and might have small difference but overall theme is to subscribe or not — we will focus on that
Tatva Chintan IPO– Incorporated in 1996, Tatva Chintan Pharma Chem Limited is a specialty chemicals manufacturing company. It is engaged in the manufacture of structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for super capacitor batteries and pharmaceutical & agrochemical intermediates & other specialty chemicals (PASC).
Business — It is the largest and the only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally. It serves customers across various industries including automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavor & fragrances
Region of operation — The company exports most of its products to over 25 countries, including the US, China, Germany, Japan, South Africa and the UK
Revenue/Product Mix – India 28%, China 18%, US 15%, Others 39%
SDA 40%, PASC 31%, PTC 28%, Electrolyte Salts 1%
Offer purpose — The IPO is fresh issuance of shares worth ₹225 crore and an offer for sale to the tune of ₹275 crore by existing promoters and shareholders.Proceeds from the fresh issue would be used towards funding capital expenditure requirements for expansion of the company’s Dahej manufacturing facility; up-gradation of research and development facility in Vadodara; and general corporate purposes.
Risks —
Revenue of 60% from Top 10 Customers leads to concentration risk
Highly competitive industry and well established peers like Aarti Industries Limited, PI Industries Limited, Fine
Organic Industries Limited, Delta Finochem, Dishman group
High Expenses on raw materials (~50% of total expenses)
Strength
It is the largest and the only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally
Marquee list of customers Bayer, Merck, Navin Flourine, Divis,SRF, Atul, Laurus.
Strong long-term relationship with key customers with 53% customers with it over 5 years
Consistent track record of financial performance.
International presence with export to several countries i.e. China, USA, Japan etc.
Future
Company has been growing well in revenue and profitability. Unique products and diversified portfolio may help the company to retain growth path. Competition is high and will increase in coming years. Expansion and investment into R&D will help company for next phase of growth
Valuations
Valuations are as per bull market and comparatively lesser than peers
Should we apply?
People can subscribe for long term and keep on adding on dips & review holdings with each quarter earnings
Expecting strong listing gains.
Also Read
Burger King IPO crisp Summary — Listing with huge gains as shared
CAMS IPO crisp summary — Listed with 20% gains as shared
Happiest Minds IPO crisp summary –Listed with substantial gains as shared
In case you have any questions/ queries, please feel free to reach me through Contact Form
Do spread the word among your peers, family members or anyone who can benefit from this blog and asked them to subscribe. But be selfish and take care of yourself first by subscribing before they do.
Enjoy the day and your life. Don’t forget, we are alone in this grand universe and may not get a chance to live again.